Fredag 4 Juli | 04:40:25 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2025-11-06 07:00 Kvartalsrapport 2025-Q3
2025-07-17 07:00 Kvartalsrapport 2025-Q2
2025-05-28 - X-dag ordinarie utdelning CAMX 0.00 SEK
2025-05-27 - Årsstämma
2025-05-15 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-07-16 - Kvartalsrapport 2024-Q2
2024-05-10 - X-dag ordinarie utdelning CAMX 0.00 SEK
2024-05-08 - Årsstämma
2024-05-08 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-07-18 - Kvartalsrapport 2023-Q2
2023-05-11 - X-dag ordinarie utdelning CAMX 0.00 SEK
2023-05-10 - Årsstämma
2023-05-10 - Kvartalsrapport 2023-Q1
2023-02-14 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-07-15 - Kvartalsrapport 2022-Q2
2022-05-13 - X-dag ordinarie utdelning CAMX 0.00 SEK
2022-05-12 - Årsstämma
2022-05-12 - Kvartalsrapport 2022-Q1
2022-02-16 - Bokslutskommuniké 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-07-15 - Kvartalsrapport 2021-Q2
2021-05-07 - X-dag ordinarie utdelning CAMX 0.00 SEK
2021-05-06 - Årsstämma
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-11 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-16 - Kvartalsrapport 2020-Q2
2020-05-08 - X-dag ordinarie utdelning CAMX 0.00 SEK
2020-05-07 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-12 - Bokslutskommuniké 2019
2019-11-08 - Kvartalsrapport 2019-Q3
2019-07-18 - Kvartalsrapport 2019-Q2
2019-05-10 - X-dag ordinarie utdelning CAMX 0.00 SEK
2019-05-09 - Årsstämma
2019-05-09 - Kvartalsrapport 2019-Q1
2019-02-06 - Bokslutskommuniké 2018
2018-10-25 - Kvartalsrapport 2018-Q3
2018-07-17 - Kvartalsrapport 2018-Q2
2018-05-04 - X-dag ordinarie utdelning CAMX 0.00 SEK
2018-05-03 - Årsstämma
2018-05-03 - Kvartalsrapport 2018-Q1
2018-02-15 - Bokslutskommuniké 2017
2017-10-26 - Kvartalsrapport 2017-Q3
2017-07-13 - Kvartalsrapport 2017-Q2
2017-05-04 - X-dag ordinarie utdelning CAMX 0.00 SEK
2017-05-03 - Årsstämma
2017-05-03 - Kvartalsrapport 2017-Q1
2017-02-16 - Bokslutskommuniké 2016
2016-10-22 - Kvartalsrapport 2016-Q3
2016-07-14 - Kvartalsrapport 2016-Q2
2016-05-17 - Kvartalsrapport 2016-Q1
2016-05-04 - X-dag ordinarie utdelning CAMX 0.00 SEK
2016-05-03 - Årsstämma
2016-03-30 - Bokslutskommuniké 2015

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriBioteknik
Camurus är verksamt inom bioteknik. Bolaget drivs som ett forskningsbaserat läkemedelsbolag och utvecklar samt distribuerar produkter för behandling av svåra och kroniska sjukdomar. Sjukdomar som behandlas med bolagets produkter innefattar exempelvis cancer, endokrina störningar samt patienter med opioidberoende. Camurus driver utvecklingsprojekt i egen regi samt i partnerskap med internationella läkemedelsbolag. Bolaget har sitt säte i Lund.
2021-09-15 09:00:00

Lund, Sweden - 15 September 2021 - Camurus (NASDAQ STO: CAMX) today announced that Eva Pinotti-Lindqvist has decided to leave her position in the company. The company has initiated a process to recruit a successor. Eva has held her position in the company since June 2014 and will continue in her present role until a new CFO has been appointed.

"Eva has during her seven years as CFO with Camurus played an important role in the development of Camurus from a R&D based organization to a successful international pharmaceutical company," says Fredrik Tiberg, President and CEO. "I would like to extend a warm thank you to Eva for her significant contribution to Camurus' positive development over the past seven years. Eva has been a dedicated and highly appreciated colleague and we wish her all the best when she now has decided to leave her position as CFO of the company."

"I am grateful for having had the opportunity to serve as CFO and member of Camurus' Executive Management Team and be part of a very positive and exciting period of the company's development, including the IPO and successful launches of our first pharmaceutical product," says Eva Pinotti-Lindqvist. "Camurus has a great potential and is a fantastic organization and I am convinced that this is only the beginning of a successful growth journey."

About Camurus
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal[®] drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com

Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com

This information was submitted for publication at 9:00 am CET on 15 September 2021.